Akari Therapeutics Stock Jumps On Promising Preclinical Data - Akari Therapeutics (NASDAQ:AKTX)

Akari Therapeutics shares are surging after preclinical data showed AKTX‑101 synergized with KRAS inhibition in pancreatic cancer models.

Raccontata dabenzinga.com